0000000000591965

AUTHOR

Peter Bramlage

showing 3 related works from this author

The role of heparin lead-in in the real-world management of acute venous thromboembolism: The PREFER in VTE registry

2017

Abstract Introduction The appropriate strategy for initiating oral anticoagulant (OAC) therapy after an acute venous thromboembolism (VTE) depends on the intermediate-term anticoagulant to be used. While heparin bridging to vitamin K antagonists (VKA) is required, the direct oral anticoagulants (DOAC) rivaroxaban (30 mg/day) and apixaban (10 mg/day) can be initiated directly without parenteral anticoagulation. The objective was to evaluate OAC initiation patterns in clinical practice. Materials and methods PREFER in VTE was an international, non-interventional registry conducted between January 2013 and August 2015. Consecutive acute VTE patients were grouped based on their OAC treatment at…

Malemedicine.medical_specialtymedicine.drug_class030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansRegistries030212 general & internal medicineIntensive care medicineLead (electronics)RivaroxabanAnticoagulants; Heparin; Rivaroxaban; Venous thromboembolism; Warfarin; Acute Disease; Anticoagulants; Female; Heparin; Humans; Male; Middle Aged; Registries; Venous Thromboembolism; HematologyHeparinbusiness.industryAnticoagulantWarfarinAnticoagulantsVenous ThromboembolismHematologyHeparinMiddle Agedmedicine.diseasePulmonary embolismAcute DiseaseFemaleApixabanWarfarinbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

The Adverse Events and Hemodynamic Effects of Adenosine-Based Cardiac MRI

2011

OBJECTIVE We wanted to prospectively assess the adverse events and hemodynamic effects associated with an intravenous adenosine infusion in patients with suspected or known coronary artery disease and who were undergoing cardiac MRI. MATERIALS AND METHODS One hundred and sixty-eight patients (64 ± 9 years) received adenosine (140 µg/kg/min) during cardiac MRI. Before and during the administration, the heart rate, systemic blood pressure, and oxygen saturation were monitored using a MRI-compatible system. We documented any signs and symptoms of potential adverse events. RESULTS In total, 47 out of 168 patients (28%) experienced adverse effects, which were mostly mild or moderate. In 13 patie…

AdultGadolinium DTPAMalemedicine.medical_specialtyAdenosineVasodilator AgentsDiastoleHemodynamicsContrast MediaBlood PressureCoronary DiseaseChest painCoronary artery diseaseCoronary artery diseaseHeart RateInternal medicineHeart ratemedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesAdverse effectInfusions IntravenousAgedAged 80 and overbusiness.industryHemodynamicsMiddle Agedmedicine.diseaseAdenosineMagnetic Resonance ImagingOxygenBlood pressureAnesthesiaAdverse eventsCardiologyOriginal ArticleFemalemedicine.symptombusinessmedicine.drugMRIKorean Journal of Radiology
researchProduct

Results of the Dyslipidemia International Study (DYSIS)-Middle East: Clinical Perspective on the Prevalence and Characteristics of Lipid Abnormalitie…

2013

BACKGROUND: Therapeutic intervention with low-density lipoprotein cholesterol-lowering agents known as statins has been demonstrated to reduce cardiovascular risk. However, many patients on statin treatment have persistent dyslipidemia and remain at a high risk of cardiovascular disease. Therefore, the objective of this study was to assess the frequency of lipid abnormalities in patients receiving chronic statin treatment. METHODS: As part of an international, cross-sectional, observational study, DYSIS-Middle East enrolled 2,182 patients in the United Arab Emirates (UAE), Saudi Arabia, Lebanon and Jordan. All patients were over 45 years of age and had been on statin treatment for at least …

Malemedicine.medical_specialtyCross-sectional studylcsh:MedicineComorbidityDiseaseMiddle Eastchemistry.chemical_compoundRisk FactorsInternal medicineDiabetes mellitusPrevalencemedicineHumanscardiovascular diseaseslcsh:ScienceAgedDyslipidemiasMultidisciplinaryCholesterolbusiness.industrylcsh:Rnutritional and metabolic diseasesMiddle AgedStatin treatmentmedicine.diseaseLipidsComorbidityCross-Sectional StudieschemistryPhysical therapyFemalelcsh:Qlipids (amino acids peptides and proteins)Hydroxymethylglutaryl-CoA Reductase InhibitorsbusinessDyslipidemiaResearch ArticleLipoproteinPLoS ONE
researchProduct